Abstract
Background
Agitation in Alzheimer's disease significantly impacts patient outcomes and caregiver burden. Brexpiprazole has emerged as a promising treatment option, but optimal dosing remains unclear.
Objective
To evaluate the comparative efficacy and safety of different brexpiprazole doses in treating agitation associated with Alzheimer's disease through a systematic review and network meta-analysis (NMA).
Methods
Following PRISMA guidelines, we searched PubMed, Embase, Web of Science, and Scopus through January 2025. Four randomized controlled trials (N = 1451) comparing various brexpiprazole doses (0.5–3 mg/day) with placebo were included. Primary outcomes included changes in the Cohen-Mansfield Agitation Inventory (CMAI), the Clinical Global Impression-Severity Scale (CGI-S), and the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) scores, alongside safety measures.
Results
Brexpiprazole 2 mg demonstrated significant improvement in CMAI scores versus placebo (mean difference [MD]: −5.88; 95% CI: −8.13 to −3.63) and CGI-S scores (MD: −0.48; 95% CI: −0.95 to −0.01). Multiple doses showed significant NPI-NH improvements, with 2–3 mg showing the strongest effect (MD: −4.60; 95% CI: −7.54 to −1.66). Higher doses (2–3 mg) increased treatment-emergent adverse events (risk ratio [RR]: 1.20–1.33) but showed no significant difference in serious adverse events compared to placebo.
Conclusions
Brexpiprazole 2 mg provides optimal therapeutic benefit while maintaining a favorable safety profile. The findings support initiating treatment at lower doses with careful titration to 2 mg based on individual response and tolerability. Future research should focus on long-term outcomes and real-world effectiveness.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
